Europe Bone Degeneration Therapeutics Market: Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2017 to 2021 and Forecast 2022 to 2028

$ PRICE - $ 2,000.00$ 6,900.00

Europe Bone Degeneration Therapeutics Market: By Drug Type (Hyaluronic acid, Platelet rich plasma, Steroids and cortisone, Others),By Route of Administration (Oral, Parenteral), By Application (Osteopenia, Osteoarthritis, Spinal Fusion), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Homecare Settings) and by Country

 

$ PRICE - $ 2,000.00$ 6,900.00
Region Europe
Clear selection
Clear
$ PRICE - $ 2,000.00$ 6,900.00
FacebookTwitterLinkedinEmail
SKU: N/A Category:

Report

Description

Europe Bone Degeneration Therapeutics market size is valued at USD xx million in 2021 and is expected to grow at a prominent growth rate 3.8% during the forecast period 2022 to 2028. The European market provides a detailed overview of the Europe Bone Degeneration Therapeutics market, and that can be segmented by drug type, by route of administration, and by application. By drug type, The Europe Bone Degeneration Therapeutics market has been segmented into Hyaluronic acid, Platelet-rich plasma, Steroids, and cortisone, among Others. The Platelet – Rich Plasma segment is likely to be the largest and fastest-growing segment in terms of drug type. The supremacy of this segment is owing to the application of platelet-rich plasma therapy in bone degeneration disease. It was found that platelet-rich plasma therapy for curing knee osteoarthritis has a high success rate and the efficiency depends on the brutality of knee osteoarthritis. However, Cortisone or steroids is projected to grow with the fastest CAGR during the forecast period. It is mainly because corticosteroid injections can cure various spinal conditions and skeletal, and muscular. Dexamethasone, prednisone, methylprednisolone, and hydrocortisone are FDA-approved corticosteroid injections utilized to decrease inflammation and pain. Such characteristics of corticosteroid injections and their need for numerous bone diseases and injuries fuel the growth of the Bone Degeneration Therapeutics Market Share. Based on the Route of administration, the Europe Bone Degeneration Therapeutics market is segmented into Oral, Parenteral. Among these, the Parenteral segment is expected to have a significant growing market during the forecast period 2022-2028. Based on the Application, the Europe Bone Degeneration Therapeutics market is segmented into Osteopenia, Osteoarthritis, and Spinal Fusion. The Osteoarthritis segment accounts for the largest share in 2021. Based on the distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Homecare Settings. The Hospital Pharmacies segment accounts for the largest share in 2021.

Key Developments:

In August 2021, CTI Biopharma Corporation and DRI Healthcare Trust announced the funding of pacrinitib sales and subsequent product approval by the US Food and Drug Administration (FDA).

In October 2019, Amgen acquired Teneobio, Inc

Europe Bone Degeneration Therapeutics Market

MARKET SUMMARY
-
3.8% CAGR
  • Study Period– 2021 – 2027
  • Base Year– 2020
  • CAGR– 3.8%

Europe Bone Degeneration Therapeutics Market

  • europe bone degeneration therapeutics market report gives comprehensive outlook across the region with special emphasis on key regions such as United Kingdom, Germany, Italy, Spain, London, France, and rest of the Europe countries.
  • The report on europe bone degeneration therapeutics market gives historical, current and future market sizes (US$ Mn) based on drug type, route of administration, application, distribution channel and by country.
Key Players
  • Amgen, Inc. (U.S.)
  • Bone Therapeutics SA (Belgium)
  • Fate Therapeutics (U.S.)
  • Regenexx (U.S.)
Europe Bone Degeneration Therapeutics Market Drivers

Europe Bone Degeneration Therapeutics market is chiefly driven by the growing aging population and increasing cases of injuries and accidents.


Germany Got Significant Share

Europe Bone Degeneration Therapeutics Market

By countries, Germany, Italy, UK, France, Spain, Russia, and Poland market is expected to witness the highest market share during the forecast period.

Latin America
Latin-America
North-America
North-America
Europe
Europe
Asia Pacific
Asia-Pacific
Middle East
Middle East

Key

Features of the Report

  • The Europe bone degeneration therapeutics market provides granular level information about the market size, regional market share, historic market (2017-2021) and forecast (2022-2028)
  • The Europe bone degeneration therapeutics market covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
  • The Europe bone degeneration therapeutics market outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The Europe bone degeneration therapeutics market tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The Europe bone degeneration therapeutics market provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Europe Bone Degeneration Therapeutics Market Segmentation


Location

GEOGRAPHY

Frequently Asked Questions

The europe bone degeneration therapeutics market is projected to expand at a CAGR of 3.8% during the forecast period

Amgen, Inc. (U.S.), Bone Therapeutics SA (Belgium), Fate Therapeutics (U.S.), Regenexx (U.S.), Fate Therapeutics (U.S.), Amgen, Inc. (U.S.), Regenexx (U.S.), Bone Therapeutics SA (Belgium)


Report

Table Of Content


Report

Company Profile

  • Fate Therapeutics (U.S.)
  • Amgen, Inc. (U.S.)
  • Regenexx (U.S.)
  • Bone Therapeutics SA (Belgium)

Description

Europe Bone Degeneration Therapeutics market size is valued at USD xx million in 2021 and is expected to grow at a prominent growth rate 3.8% during the forecast period 2022 to 2028. The European market provides a detailed overview of the Europe Bone Degeneration Therapeutics market, and that can be segmented by drug type, by route of administration, and by application. By drug type, The Europe Bone Degeneration Therapeutics market has been segmented into Hyaluronic acid, Platelet-rich plasma, Steroids, and cortisone, among Others. The Platelet – Rich Plasma segment is likely to be the largest and fastest-growing segment in terms of drug type. The supremacy of this segment is owing to the application of platelet-rich plasma therapy in bone degeneration disease. It was found that platelet-rich plasma therapy for curing knee osteoarthritis has a high success rate and the efficiency depends on the brutality of knee osteoarthritis. However, Cortisone or steroids is projected to grow with the fastest CAGR during the forecast period. It is mainly because corticosteroid injections can cure various spinal conditions and skeletal, and muscular. Dexamethasone, prednisone, methylprednisolone, and hydrocortisone are FDA-approved corticosteroid injections utilized to decrease inflammation and pain. Such characteristics of corticosteroid injections and their need for numerous bone diseases and injuries fuel the growth of the Bone Degeneration Therapeutics Market Share. Based on the Route of administration, the Europe Bone Degeneration Therapeutics market is segmented into Oral, Parenteral. Among these, the Parenteral segment is expected to have a significant growing market during the forecast period 2022-2028. Based on the Application, the Europe Bone Degeneration Therapeutics market is segmented into Osteopenia, Osteoarthritis, and Spinal Fusion. The Osteoarthritis segment accounts for the largest share in 2021. Based on the distribution channel, the market is segmented into Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Homecare Settings. The Hospital Pharmacies segment accounts for the largest share in 2021.

Key Developments:

In August 2021, CTI Biopharma Corporation and DRI Healthcare Trust announced the funding of pacrinitib sales and subsequent product approval by the US Food and Drug Administration (FDA).

In October 2019, Amgen acquired Teneobio, Inc

ASIA PACIFIC OFFICE

Precision Business Insights, MIG 366, SAI PLAZA, 1st Floor, KPHB Colony, Hyderabad - 500072

EUROPE OFFICE

Precision Business Insights, Kemp House, 152 – 160 City Road, London EC1V 2NX